Agomab Reports Positive Phase 2a Results for Ontunisertib in Fibrostenosing Crohn’s Disease

FDA Expands RINVOQ® Indication for Inflammatory Bowel Disease

AstraZeneca Partners with Immunai in $85M AI-Driven IBD Deal

Phase 4 Study: Vedolizumab More Effective in Early Crohn’s Disease

CU Anschutz Study Links MAIT Cells to Gut Inflammation

SMC Approves TREMFYA® for Crohn’s Disease and Ulcerative Colitis

MRC Researchers Uncover Cell Mechanism Behind Crohn’s Fistulas

Numab and Kaken Partner on First-in-Class Multispecific Antibody for IBD

Wouter J De Jonge

Professor and Chair Experimental Gastroenterology University of Amsterdam

Thursday 2nd April 2026

Using Blood-Based Epigenetic Signatures to Personalize First-Line Biologic Therapy in Crohn’s Disease

1:45 pm

Investigating a scalable, blood-derived DNA methylation panel designed to guide first-line biologic selection at diagnosis, aiming to move beyond today’s trial-and-error paradigm and reduce early complications linked to ineffective therapy
Leveraging a validated epigenetic algorithm undergoing testing in the OMICRON clinical trial to improve therapeutic success rates
Establishing a blueprint for cross-disease precision medicine, with methylation markers and machine-learning pipelines engineered for translation